A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer

In conclusion, TEADi is a valuable research tool for studying YAP1/TAZ and the Hippo pathway in cancer and other pathologies, with improved advantages that include rapid and simple inhibition of TEAD transcription and specific blockage of nuclear events mediated by both YAP1 and TAZ without affecting structural or cytoplasmic functions of these proteins.NCI is continuing to develop this inhibitor to improve its stability and potency. The NCILaboratory of Cellular and Molecular Biologyseeks statements of capability or interest from parties interested in licensing this novel inhibitor of the Hippo signaling pathway.ID: NCI-E-108-2019John Hewes, Ph.D.John.Hewes@nih.govPhone: 240-276-5515Inventors: Ramiro Iglesias-Bartolome (NCI), Yao Yuan (NCI)Co-Inventors: Ramiro Iglesias-Bartolome (NCI), Yao Yuan (NCI)Rapid and simple inhibition of specific effectors of a signaling pathway frequently disrupted in cancerInhibition of both YAP1 and TAZ factors that regulate the Hippo pathwayInhibition of YAP/TAZ interaction with a specific family of transcription factorsGreen fluorescent protein (GFP) label for easy trackingNuclear localization signal to target hyperactivated YAP/TAZTEADi DNA construct to study Hippo signaling pathway in different pathologies and cellular systems.TEADi DNA construct to selectively shut off Hippo signaling pathway for broader research purposesDelivery of TEADi DNA construct using lentivirus, adenovirus (AV), or adeno-associated virus (AAV) for broa...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research